- FDA staff have said that Medicines Company's (NASDAQ:MDCO) Cangrelor drug for preventing blood clots should not be approved, with the treatment needing another trial in order to correct flaws in earlier studies.
- The FDA's recommendation comes ahead of a meeting of an advisory committee that is due to take place on Wednesday.
- Shares are -13%. (PR)